| Title |
Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine |
| Authors |
Söderholm, Sandra ; Anastasina, Maria ; Islam, Mohammad Majharul ; Tynell, Janne ; Poranen, Minna M ; Bamford, Dennis H ; Stenman, Jakob ; Julkunen, Ilkka ; Šaulienė, Ingrida ; de Brabander, Jef K ; Matikainen, Sampsa ; Nyman, Tuula A ; Saelens, Xavier ; Kainov, Denis |
| DOI |
10.1016/j.antiviral.2015.12.011 |
| Full Text |
|
| Is Part of |
Antiviral research.. Amsterdam : Elsevier Masson. 2016, vol. 126, p. 69-80.. ISSN 0166-3542 |
| Keywords [eng] |
influenza A virus ; antiviral agents ; innate immunity ; immune responses ; virus-host interaction |
| Abstract [eng] |
Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNa)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections. |
| Published |
Amsterdam : Elsevier Masson |
| Type |
Journal article |
| Language |
English |
| Publication date |
2016 |
| CC license |
|
